SAGE250117P15000
- 4.10
- 0.000.00%
Sage Therapeutics Newsroom
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
As Small-caps Ride the Trump Wave, Here Are the Best & Worst Such Stocks as per SA Quant
Stifel Maintains Hold on Sage Therapeutics, Lowers Price Target to $6
Sage Therapeutics Analyst Ratings
Stifel Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Cuts Target Price to $6
Mizuho Securities Maintains Sage Therapeutics(SAGE.US) With Hold Rating, Announces Target Price $10
Mizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Express News | Sage Secures $35 Million in Series B Funding to Transform Senior Living Operations Across the U.S. and Beyond
Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Agenus (AGEN) and SAGE Therapeutics (SAGE)
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $8 to $14
Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says
TD Cowen Maintains Hold on Sage Therapeutics, Lowers Price Target to $9
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $4 to $14
Truist Financial Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Sage Therapeutics Price Target Maintained With a $4.00/Share by RBC Capital
Express News | Sage Therapeutics Inc : RBC Raises to Sector Perform From Underperform
SAGE Therapeutics: Hold Rating Amid Clinical Setbacks and Strategic Shifts